Uncategorized

IPF draws investor heat as biotechs target fibrosis halt, better tolerability

Published

on

Novel targets aim to stop lung scarring—where current drugs only slow it—while improving tolerability and unlocking fibrosis in other organs next

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version